Skip to content
value.today

Paratek Pharmaceuticals Inc.

Total raised
$93 M
1 round on record
Latest round
$93 M
Jun 2014
First round on record
Jun 2014
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Paratek Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2014$93 MNo. 1$50 to $250 million

Paratek Pharmaceuticals Inc.: Raise no. 1, Jun 2014

Investors in this round

54 investors had bought by the notice of Jul 16, 2014: 54 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$93 M of $93 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,500,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Beverly Armstrong · Executive Officer
  • Dennis Molnar · Executive Officer
  • Evan Loh · Executive Officer, Director
  • Kathryn Boxmeyer · Executive Officer
  • Michael Bigham · Executive Officer, Director
  • S. Ken Tanaka · Executive Officer
  • Sean M. Johnston · Executive Officer
  • Richard Lim · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Trout Capital LLC (CRD 131489) · New York, New YorkSold in CA, CT, MA, NJ, NY
  • Ladenburg Thalmann & Co. Inc. (CRD 505) · New York, New YorkSold in CA, CO, CT, FL, IL, MA, MD, NY, TX, and outside the US

Remarks in the notice

  • On fees: “Plus up to $75,000 in expense reimbursement.”
  • On the amounts: “In addition, various noteholders converted promissory notes having an aggregate principal amount of $6,000,000 into shares of common stock.”

Signed by Evan Loh, President. Newest notice filed Jul 16, 2014 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Paratek Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2014).

    SEC Form D · Jul 2014

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2014

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Paratek Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Paratek Pharmaceuticals Inc.
NameRoleNamed in
Beverly ArmstrongExecutive officerJul 2014
Dennis MolnarExecutive officerJul 2014
Evan LohExecutive officerJul 2014
Kathryn BoxmeyerExecutive officerJul 2014
Michael BighamExecutive officerJul 2014
S. Ken TanakaExecutive officerJul 2014
Sean M. JohnstonExecutive officerJul 2014
Evan LohDirectorJul 2014
Michael BighamDirectorJul 2014
Richard LimDirectorJul 2014